What’s attractive about stocks with a market value around $1 billion? The author of today’s article explains that “At that size, a stock is small enough so that it hasn’t yet been “discovered” by a lot of Wall Street firms, but big enough to have some heft and staying power.” Each year he selects ten stocks hovering around the billion-dollar…
“Once a tried-and-true [COVID-19] vaccine is developed and subsequently incorporated as standard fare in medical practice, one driver of biotech will be mergers and acquisitions,” advises the author of today’s article. He proceeds to highlight an ETF that could benefit from this particular driving force – a fund that has generated a 30% return this year. For more, CLICK HERE.
Thanksgiving means it’s a shortened trading week – and today’s article features two biotech stocks to consider shorting this shortened week based on technical analysis and quantitative ratings. For these two biotech stocks that “look bearish and may present interesting investing opportunities on the short side,” CLICK HERE.
“When it comes to consistent profitability, long-term growth, large competitive moats, and innovation, medical device companies can provide better returns in the long run” compared to biotech stocks, advises the author of today’s article. He proceeds to highlight three medical device stocks which, while not having generated the massive returns some biotech stocks have this year, have handily beaten the…
The three biotech stocks highlighted in today’s article are ones to watch carefully in the coming weeks, advises the author, as important news drops are expected – and in the case of two of the stocks, those news drops are related to the companies’ COVID-19 vaccine candidates. For more on these three biotech stocks to watch throughout the remainder of…
The clinical-stage biotech highlighted in today’s article, dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, has been one of the hottest biotech stocks this year. And after a run-up that has generated triple-digit returns, there are a number of factors that could help propel it to even higher highs from here. For more on this…
When it comes to finding the best biotech stocks to buy, the author of today’s article acknowledges that it “can be tricky given that volatility often haunts the space.” Nonetheless, he proceeds to highlight three biotech stocks to watch – two of which are working on COVID-19 vaccines while the third may be worth a look even though the company…
In making the case for why the biotech featured in today’s article, which is focused on the development of novel antibody-drug conjugate therapeutics for the treatment of cancer, is an attractive investment, the analyst cited points to three primary factors: “the favorable outlook for [its lead candidate], the long-term potential of the biotech’s pipeline and the continuing validation, by partners,…
The biotech stock that’s the focus of today’s article recently dipped after reporting clinical trial results for its revolutionary cancer treatment “that were positive but perhaps not positive enough to outrun the competition.” So could it represent a good “buy the dip” opportunity? The author outlines the reasons to consider buying this stock, as well as some reasons to exercise…
In regards to the two relatively young biotech stocks with monster potential discussed in today’s article, the author has the following to say: “…they have deeply compelling projects that aim to cure or fully mitigate a handful of different medical conditions that were once considered intractable. Both have demonstrated excellent progress so far, not to mention financial strength. It’ll take…